Dapablix/Dapablix Met
Products and Business Services
Information
Dapablix contains dapagliflozin, an SGLT2 inhibitor that effectively reduces blood glucose levels by promoting renal glucose excretion. It is indicated for the management of type 2 diabetes mellitus, offering additional benefits such as weight reduction and cardiovascular risk mitigation.
Dapablix Met combines dapagliflozin, an SGLT2 inhibitor, and metformin, a biguanide, to enhance glycemic control in patients with type 2 diabetes. This dual mechanism targets both renal glucose excretion and hepatic glucose production, providing effective blood sugar management. Dapablix Met supports weight reduction and has a proven safety profile, making it a preferred option for comprehensive diabetes care.
Distribution Areas
AfricaMiddle East Region (e.g. UAE)Central America (e.g. Mexico)East Asia (e.g. China, Japan, Korea)Europe - non EU (e.g. UK, Russia, ex-CIS countries)South America (e.g. Brazil, Colombia)South Asia (e.g. India, Pakistan, Sri Lanka)South East Asia (e.g. Thailand, Philippines, Singapore)
Supplied From
Egypt
Main Categories
Finished Dosage Forms
